Bou Rjeily N, Fitzgerald KC, Mowry EM. Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity. Mult Scler 2023 Nov 9:13524585231208311. doi: 10.1177/13524585231208311.
PMID: 37942884